NOVARTIS Australia has announced Leqvio (inclisiran) is now available on the PBS for adults with two types of high cholesterol.
The medication is suitable for those patients diagnosed with heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia with atherosclerotic cardiovascular disease, and who can't hit their cholesterol targets with just statins and ezetimibe.
Dr Karam Kostner, A/Prof of Medicine at the University of Queensland and Director of Cardiology at Mater Hospital, Brisbane, pointed out the serious impact of heart disease in Australia and that one in three live with high cholesterol levels.
"The availability of a first-of-its-kind siRNA therapy that only requires twice-yearly dosing provides patients with another highly effective treatment option to help them control their low-density lipoprotein cholesterol (LDL-C) levels," said Kostner.
"This is a fantastic and welcome development in an area of high unmet need."
Tanya Hall from Hearts4Heart believes Leqvio is an exciting addition for patients.
"The introduction of a new treatment option is wonderful news for Australian patients.
"Continued innovation in the area of hypercholesterolaemia and atherosclerotic cardiovascular disease and timely access to the right treatment is essential for people living with these conditions," Hall commented.
Novartis Australia Country President ANZ Matt Zeller emphasised that with Leqvio on the PBS, the profession can further help improve lives.
"Given the increased burden on our healthcare system and the inequalities often faced by rural and regional patients, we believe that pharmacists can also play a key role in helping patients administer and manage the therapy," said Zeller.
Leqvio's PBS listing is backed by significant research.
The drug's phase three trial found that twice-yearly, Leqvio, in addition to statin therapy, provides consistent LDL-C reduction beyond six years of treatment. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Apr 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 24
